This chapter focuses on microneedles, hydrogels, thermal ablation, sonophoresis, and iontophoresis, highlighting current developments and future directions in MIDDS. Problems that have arisen during the clinical development of MIDDS range from issues of medication absorption to formulation stability, regulatory hurdles, and variations in patient compliance in this article. This throws light on the various therapeutic applications for which each of these MIDDS technologies is undergoing studies and gives an overview of the ongoing clinical trials involving those technologies. Advances in the areas of bio-responsive microneedles, smart integration of sonophoresis and iontophoresis, targeted delivery through novel designs in nanoparticles, responsive hydrogels, and thermal ablation techniques are expected to brighten the future prospects of MIDDS. The introduction of wireless electronics, artificial intelligence, and machine learning is going to make drug distribution, treatment personalization, and targeting efficiency take giant strides. Overall goals include obtaining better treatment results and better patient compliance by removing biological obstacles and attaining preprogrammed pulsatile release. Paper-based conclusions show that MIDDS improve patient compliance, improve patients’ adherence to treatment protocols, and also reduce overall healthcare costs since the said delivery procedures are noninvasive, rapid, and painless.